Get the Stockscreener App
1,021.90
0.47%
1.903
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,021.90, with a volume of 1.59M.
It is up +0.47% in the last 24 hours and down -4.65% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,023.80
Open:
$1025.36
24h Volume:
1.59M
Relative Volume:
0.46
Market Cap:
$915.22B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
50.54
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-5.41%
1M Performance:
-4.65%
6M Performance:
+34.82%
1Y Performance:
+27.92%
1-Day Range:
$1,018.00
$1,040.00
1-Week Range:
$1,004.14
$1,084.32
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,022.57 | 916.32B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.40 | 548.64B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
220.78 | 386.47B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
148.74 | 283.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.43 | 265.33B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Expands U.S. Manufacturing with Six New Plants - GuruFocus
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Benzinga
Trump says Eli Lilly to build six US plants By Reuters - Investing.com
Eli Lilly (LLY) Inks $1.12 Billion Deal with ‘Gene-Editing’ Firm Seamless - TipRanks
Eli Lilly Invests Billions to Diversify Beyond Blockbuster Drugs - AD HOC NEWS
Lilly, Repertoire strike $2 billion autoimmune alliance - statnews.com
Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases - PharmTech.com
Eli Lilly (LLY) Partners with Repertoire in $1.9B Autoimmune Tre - GuruFocus
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
Lilly to partner with Cambridge biotech to fight autoimmune diseases in $85 million deal - The Boston Globe
Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead. - The Motley Fool
Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $1.9B - Fierce Biotech
Eli Lilly, a global pharmaceutical company that has secured all-time cash with the obesity drug "Jeb.. - 매일경제
Eli Lilly’s Billion-Dollar Bet on Genetic Medicine - AD HOC NEWS
Eli Lilly Extends Beyond GLP-1s With Gene Editing And Oncology Push - simplywall.st
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. - AOL.com
Donanemab by Eli Lilly and Company expected to drive market size of Alzheimer's Disease - openPR.com
Eli Lilly’s Strategic Expansion into Genetic Medicine - AD HOC NEWS
Seamless seals $1.12B gene editing deal with Lilly on hearing loss - BioWorld MedTech
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership - Pharmaceutical Technology
Eli Lilly partners with Seamless Therapeutics on gene editing treatments for hearing loss - Proactive financial news
Eli Lilly (LLY) Partners with Seamless Therapeutics in $1.12B Ge - GuruFocus
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless - Reuters
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows - Reuters
Eli Lilly expands work on gene therapies for hearing - statnews.com
Eli Lilly and Company (LLY): A Bull Case Theory - Finviz
Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss - Stocktwits
LLY Partners with Seamless Therapeutics for Hearing Loss Treatme - GuruFocus
Here’s Why Eli Lilly (LLY) is Surging - Yahoo Finance
Eli Lilly Bolsters Pipeline with Billion-Dollar Biotech Partnership - AD HOC NEWS
Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership - TipRanks
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Pennant Group (PNTG) and Warby Parker (WRBY) - The Globe and Mail
Lilly Signs Seamless Gene-Editing Deal for Over $1.1 Billion - Bloomberg.com
Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows - Yahoo! Finance Canada
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,145 - 富途牛牛
Eli Lilly (LLY) Drives Q4 Gains as Pharma Fundamentals Shine Amid Sector Rotation - Finviz
Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration - Genetic Engineering and Biotechnology News
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Reuters
1 Pharmaceutical Stock Set to Rebound in 2026 - AOL.com
Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view - TechStock²
Citigroup Maintains Street-High $1,500 Price Target on Eli Lilly Stock (LLY) - TipRanks
Up 36%, Is Eli Lilly Still a Buy? - The Motley Fool
Where Will Eli Lilly Be in 10 Years? - Finviz
Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo - Reuters
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth - Insider Monkey
Eli Lilly and Company $LLY Shares Bought by Phoenix Financial Ltd. - MarketBeat
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder - BioSpace
Roche claims obesity drug caused 22.5% weight loss as it aims to catch up with Lilly, Novo - Business Day
Eli Lilly and Company (NYSE:LLY) Stock Acquired Sen. Angus S. King Jr. - MarketBeat
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):